Printer Friendly

Articles from M2 Pharma (June 4, 2018)

1-30 out of 30 article(s)
Title Author Type Words
Ally Bridge Group reports investment in Quantum Surgical. 113
Amorsa Therapeutics names new director. 176
Aratana submits label expansion of NOCITA analgesic under US FDA NADA. 173
Athletico appoints Melissa McMahon as SVP of Human Resources. 149
BDD Pharma Licenses Timed-release OralogiK Technology to Novartis. 195
CellMax Life Commences US Clinical Study of Blood Tests for Early Cancer Detection. Clinical report 272
Ectosense names Ciaran McCourt as CEO. 162
Eli Lilly and Company & Incyte pass US FDA approval for 2-mg dose of OLUMIANT for treating rheumatoid arthritis. 306
FDA Approves Generic Cyclophosphamide for Injection. 155
FDA Challenges Innovators to Develop Medical Devices to Aid in Resolution of Opioid Addiction Crisis. 373
FDA Grants Priority Review Designation for Eisai's Fycompa (perampanel) in Pediatric Seizure Control. 298
GlaxoSmithKline names new senior VP, head of worldwide business development for pharmaceutical research and development. 135
IM announces Fiber Choice Fiber Supplement as the number one recommended brand nationwide in national survey. 297
Janssen Begins Phase 1b/2 Clinical Development Program Evaluating CAR-T Cells for Treatment of Multiple Myeloma. 211
Lannett awarded US FDA approval for Levofloxacin Oral Solution, with expected imminent launch. 170
Madrigal Pharmaceuticals' MGL-3196 achieves endpoints in patients with non-alcoholic steatohepatitis in phase two clinical trial. Clinical report 197
Novartis reveals positive results from third Phase III Kisqali combination therapy trial. 235
Processa Pharmaceuticals announces USD6.88m from private placements. 247
ReShape Lifesciences' board authorises one for-15 reverse stock split. 169
Sosei appoints Chris Cargill as interim CFO. 173
Syndax Pharmaceuticals signs non-exclusive immuno-oncology clinical trial collaboration with Nektar Therapeutics. 244
Syndax, Nektar Therapeutics Collaborate on Immuno-Oncology Clinical Trial. 307
The Combinations Alliance launches clinical trial testing in leukaemia patients. 228
Titan Pharmaceuticals, Braeburn End License Agreement for Probuphine For Opioid Dependence. 226
Trial suggests fewer early breast cancer patients will need chemotherapy. 772
Upsher-Smith signs exclusive distribution agreement for six ophthalmic/Otic ANDAs, with combined annual sales of USD1.6bn. 167
USPTO Approves Oramed Oral Protein Administration Technology. 145
Versartis agrees merger with Aravive Biologics. 225
Viveve Medical agrees patent settlement with Thermi. 156
Xeljanz Receives FDA Approval for Treatment of Moderately to Severely Active Ulcerative Colitis. 270

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters